Replies to post #196823 on Biotech Values

[DewDiligence]

CBYL -2%/AH on mixed phase-3 data in OA:

http://finance.yahoo.com/news/carbylan-therapeutics-reports-top-line-210100871.html

In the COR1.1 study, Hydros-TA met the first of its two primary endpoints, demonstrating a statistically significant improvement from baseline in the WOMAC A pain score at week 2 versus Hydros (hyaluronic acid alone). In addition, Hydros-TA maintained a significant reduction in pain from baseline over 26 weeks.

However, patients in the TA arm [one of the two control arms] continued to show an unexpected significant reduction in pain through 26 weeks. Given the comparable effectiveness at 26 weeks, COR1.1 did not meet its second primary endpoint.